Immunotherapy in Gynecologic Cancers: Are We There Yet? - Wikidata - wikimedia - TriplyDB

Immunotherapy in Gynecologic Cancers: Are We There Yet?

Immunotherapy in Gynecologic Cancers: Are We There Yet?

http://www.wikidata.org/entity/Q38608730

about

Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy The effect of Ganoderma lucidum extract on immunological function and identify its anti-tumor immunostimulatory activity based on the biological network

P2860

Q56889963-D6CE5605-12D6-47C5-B474-FB87175081CE Q57072711-504C80DA-8EEA-447E-95CD-D6A68840B5DD Q58714319-98B1D37C-CDCC-4A2D-89DF-8EEF9BE023B0

P2860

Immunotherapy in Gynecologic Cancers: Are We There Yet?

http://www.wikidata.org/entity/Q38608730

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Immunotherapy in Gynecologic Cancers: Are We There Yet?

@en

type

label

Immunotherapy in Gynecologic Cancers: Are We There Yet?

@en

prefLabel

Immunotherapy in Gynecologic Cancers: Are We There Yet?

@en

P1433

Q38608730-803B70AD-67EE-43E8-A41F-070162ED7D5A

P1476

Q38608730-DA9578E2-7059-4D02-8B94-B9AD8E76CAC9

P2093

Q38608730-11C6FF04-C73C-48E1-A60A-2AEC4A541724

Q38608730-1ABA73DE-FBD2-45E6-8FAF-CD30E1CF7A0F

P2860

Q38608730-0A5B0242-DDBB-4A30-94FA-D0384F9D6E5B

Q38608730-20CBDEF6-D482-4AD5-BDDA-5EA921F81DF1

Q38608730-2A7DA894-9BB7-4D58-8C12-DDB9FA82F5D0

Q38608730-2E7913F8-ECBF-4040-AFA1-607EEFB65D26

Q38608730-30C7A1DF-1D5E-4D07-B403-2A79D2248C5A

Q38608730-3D3F353E-F5A4-4739-9737-5540B4EC5B28

Q38608730-42B6F3E8-97DF-4EFE-8BC9-89E2D0201B1E

Q38608730-4DFF8D0D-23A6-42B7-9275-09B615F23DB4

Q38608730-4F8A7571-8D49-4E63-9291-C160C897F213

Q38608730-59EE9668-D5A5-4B24-BC3E-14545010FE4B

P2888

Q38608730-E26C2155-3323-43D0-8872-ABE40B8139E9

P304

Q38608730-1AD4875B-951F-4722-B673-CE3B1B8E2FD7

P31

Q38608730-4EF254AD-9BF3-469B-B1AD-EF7820FCB087

P356

Q38608730-ADFCB0D6-64F6-401B-9632-675FE5087697

P433

Q38608730-2143EE4D-8111-47D7-90A7-CAB9E0F6BF76

P478

Q38608730-2396D465-96AD-4481-BB16-DED44FD052E0

P577

Q38608730-D6BF678F-0AAF-452A-9896-EF50D197686F

P6179

Q38608730-1735126A-4C93-4AD5-9EF3-EFF668CE7E49

P698

Q38608730-56AFE758-898A-44AE-8A6F-9EE6C361F3AA

P921

Q38608730-2CDB2A1A-58EA-464C-92F2-7B4C0A498101

P932

Q38608730-6FDDF193-4766-454C-B914-2C9AB75D8F93

P356

S11864-017-0504-Y

P1433

Current Treatment Options in Oncology

P1476

Immunotherapy in Gynecologic Cancers: Are We There Yet?

@en

P2093

Amir A Jazaeri

http://www.w3.org/2001/XMLSchema#string

Janelle B Pakish

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

The three Es of cancer immunoediting

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

P2888

s11864-017-0504-y

P304

59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11864-017-0504-Y

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091325835

http://www.w3.org/2001/XMLSchema#string

P698

28840453

http://www.w3.org/2001/XMLSchema#string

P921

P932

5936621

http://www.w3.org/2001/XMLSchema#string